Peptides and Heparin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Peptides, Heparin), By Application (Oncology, Metabolic Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Anticoagulation Therapy, Others), By Route of Administration (Injectable, Oral, Others), By End User (Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 13.41 Billion
CAGR (2026-2031)	8.37%
Fastest Growing Segment	Metabolic Diseases
Largest Market	North America
Market Size (2031)	USD 21.72 Billion

Market Overview

The Global Peptides and Heparin Market will grow from USD 13.41 Billion in 2025 to USD 21.72 Billion by 2031 at a 8.37% CAGR. Peptides are defined as short chains of amino acids that regulate specific biological activities, while heparin is a sulfated glycosaminoglycan acting as a critical anticoagulant agent. The market is primarily driven by the escalating global prevalence of chronic metabolic and cardiovascular conditions, which necessitates continuous therapeutic intervention. According to the International Diabetes Federation, in 2025, approximately 589 million adults were estimated to be living with diabetes globally, a factor directly amplifying the demand for peptide-based management solutions. Furthermore, advancements in chemical synthesis technologies have improved the stability and bioavailability of these therapeutics, supporting their expanded application in clinical settings.

However, a significant challenge hindering market expansion is the fragility of the supply chain, particularly regarding the sourcing of raw materials for heparin production. The industry relies heavily on porcine intestinal mucosa, making it susceptible to disruptions from livestock disease outbreaks and contamination risks. This dependence on animal-derived inputs, coupled with stringent regulatory standards for impurity control, creates potential manufacturing bottlenecks and supply shortages that could impede the broader distribution and accessibility of these essential drugs.

Key Market Drivers

The increasing prevalence of cardiovascular and metabolic diseases is acting as a primary catalyst for the peptide therapeutics sector, particularly due to the success of Glucagon-like Peptide-1 (GLP-1) receptor agonists. These peptide-based biologics have transformed disease management by offering glycemic control and weight reduction, necessitating large-scale manufacturing expansion. This clinical adoption is evidenced by substantial financial growth. According to Novo Nordisk, November 2024, in the 'Financial report for the period 1 January 2024 to 30 September 2024', sales within the Diabetes and Obesity care segment increased by 25% driven by the demand for GLP-1 treatments. Such momentum underscores the critical role peptides play in addressing metabolic disease burdens.

Simultaneously, the rising incidence of coagulation disorders and thromboembolic events continues to anchor the demand for heparin as an essential anticoagulant. The risk of venous thromboembolism remains a priority, sustaining reliance on these agents in critical care settings. The scale of this challenge is significant; according to the International Society on Thrombosis and Haemostasis, October 2024, in a press release for World Thrombosis Day, statistics indicate that one in four deaths worldwide is related to conditions associated with thrombosis. This need is reinforced by regulatory support for innovation. According to BioSpace, January 2025, in the '2024 FDA Approvals: 50 New Drugs' report, peptide and nucleic acid-based therapies accounted for approximately 10% of all new FDA-approved drugs in recent years, highlighting the robust pipeline.

Download Free Sample Report

Key Market Challenges

The fragility of the supply chain, specifically the industry's acute dependence on porcine intestinal mucosa, stands as a formidable barrier to the growth of the global peptides and heparin market. Because heparin production relies almost exclusively on animal-derived raw materials, the sector is inherently exposed to volatility caused by livestock diseases and trade disruptions. When outbreaks occur, the availability of healthy porcine mucosa declines, causing immediate bottlenecks in the manufacturing of Active Pharmaceutical Ingredients (APIs). This scarcity drives up procurement costs and restricts the volume of finished therapeutics available to meet clinical demand, effectively placing a ceiling on market expansion despite rising patient needs.

Consequently, manufacturers struggle to maintain consistent inventory, resulting in supply instability that directly impedes revenue generation and reliable distribution. These interruptions prevent the market from fully capitalizing on the escalating prevalence of cardiovascular conditions. The severity of these supply constraints is evident in recent industry figures. According to the American Society of Health-System Pharmacists, in 2025, the healthcare sector reported 214 active drug shortages in the third quarter, with heparin remaining a persistently difficult-to-source sterile injectable due to these ongoing raw material and manufacturing vulnerabilities.

Key Market Trends

The transition to oral peptide delivery architectures is fundamentally reshaping the market by overcoming the historical reliance on injectable formulations for chronic metabolic conditions. Developers are actively integrating novel permeation enhancers and stabilizing technologies to improve the bioavailability of oral therapeutics, thereby addressing patient adherence challenges associated with daily injections. This shift towards non-invasive administration is substantiated by recent clinical milestones in obesity management. According to Viking Therapeutics, August 2025, in the 'Phase 2 VENTURE-Oral Dosing' trial results, patients receiving the oral tablet formulation of the dual agonist VK2735 achieved a mean weight loss of up to 12.2% after 13 weeks, demonstrating that oral peptides can effectively compete with established injectable standards.

Simultaneously, the advancement of Peptide Drug Conjugates (PDCs) for targeted oncology is expanding the sector's therapeutic footprint beyond metabolic and cardiovascular indications. PDCs utilize small peptide moieties to deliver cytotoxic payloads with high precision, offering superior tissue penetration and faster clearance rates compared to larger antibody-drug conjugates. This modality is gaining traction as a strategy to minimize systemic toxicity while maximizing potency against solid tumors. The clinical potential of this approach is evident in recent efficacy data; according to Bicycle Therapeutics, January 2025, in the 'Phase 1 Duravelo-1 trial' update, the company reported an overall response rate of 65% in patients with metastatic urothelial cancer treated with the conjugate zelenectide pevedotin.

Segmental Insights

Based on current market intelligence, the Metabolic Diseases segment is emerging as the fastest-growing area within the Global Peptides and Heparin Market. This rapid expansion is primarily driven by the escalating global prevalence of lifestyle-associated conditions, specifically type 2 diabetes and obesity. Pharmaceutical advancements have led to the introduction of highly effective peptide-based therapies, including GLP-1 receptor agonists, which provide improved outcomes in weight management and glycemic control. Furthermore, continued approvals by regulatory agencies such as the US FDA for new therapeutic indications have widened patient eligibility. These factors collectively stimulate robust demand, positioning the segment at the forefront of market growth.

Regional Insights

North America maintains a dominant position in the global peptides and heparin market, driven primarily by established pharmaceutical infrastructure and substantial healthcare expenditure in the United States. The region faces a high prevalence of chronic conditions, including metabolic disorders and cancer, which necessitates the widespread use of peptide therapeutics and anticoagulants. Additionally, the United States Food and Drug Administration provides structured regulatory pathways that facilitate the approval of novel biologics. The continuous investment in research and development by major industry players within this geography further reinforces its leading market standing.

Recent Developments

• In July 2024, CordenPharma committed to a strategic investment of €900 million to substantially expand its peptide manufacturing platform across the United States and Europe over a three-year period. This transformational initiative involved increasing capacity at its existing site in Colorado and constructing a new state-of-the-art greenfield facility in Europe to handle both early-stage and commercial-scale production. The investment was a direct response to multiple long-term contracts and the surging market demand for glucagon-like peptide-1 (GLP-1) agonists used in diabetes and obesity management, positioning the company to meet stringent quality standards for synthetic peptide manufacturing.
• In June 2024, Laboratorios Farmacéuticos ROVI announced the completion of a strategic expansion at its industrial complex in Escúzar, Spain, which included the commissioning of a new production line dedicated to sodium heparin. The company invested €11 million in this facility upgrade, which was authorized to commence commercial activity and was projected to produce up to 88 million syringes of sodium heparin annually. This development significantly bolstered ROVI's vertical integration strategy for its low-molecular-weight heparin franchise, reinforcing its manufacturing capacity and solidifying its standing as a key European producer in the global heparin market.
• In May 2024, Eli Lilly announced a historic investment of $5.3 billion to expand its manufacturing campus in Lebanon, Indiana, specifically to enhance the production of active pharmaceutical ingredients for its peptide-based therapies. This major capital commitment was driven by the unprecedented global demand for tirzepatide, the active ingredient in its treatments for type 2 diabetes and obesity. The project represented the largest single investment in synthetic medicine manufacturing in the company's history and was designed to support the pipeline growth of its incretin-based peptide medicines, ensuring broader patient access to these critical treatments in the coming years.
• In April 2024, Hamlet BioPharma secured a significant agreement with PolyPeptide Group, a leading contract development and manufacturing organization, to establish large-scale commercial production of the Alpha1 peptide. This strategic collaboration was established to guarantee the supply of the peptide active pharmaceutical ingredient necessary for Hamlet BioPharma's clinical trial program targeting bladder cancer, which was progressing toward Phase III studies. The partnership utilized PolyPeptide Group’s extensive manufacturing capabilities to ensure Good Manufacturing Practice (GMP) compliance and supply chain stability for the peptide-based drug candidate, marking a critical milestone in the drug's path to potential market approval.

Key Market Players

• Eli Lilly and Company
• Novo Nordisk A/S
• Sanofi S.A.
• Pfizer Inc.
• Takeda Pharmaceutical Co Ltd.
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Biofer SpA
• Cipla Limited
• Aspen Pharmacare Holdings Limited

By Type	By Application	By Route of Administration	By End User	By Region
Peptides Heparin	Oncology Metabolic Diseases Cardiovascular Diseases Neurological Disorders Infectious Diseases Anticoagulation Therapy Others	Injectable Oral Others	Hospitals and Clinics Research Institutes and Laboratories Pharmaceutical and Biotechnology Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Peptides and Heparin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peptides and Heparin Market, By Type:

• Peptides
• Heparin

• Peptides and Heparin Market, By Application:

• Oncology
• Metabolic Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Anticoagulation Therapy
• Others

• Peptides and Heparin Market, By Route of Administration:

• Injectable
• Oral
• Others

• Peptides and Heparin Market, By End User:

• Hospitals and Clinics
• Research Institutes and Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

• Peptides and Heparin Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE